Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSP9v3 With Metronomic Temozolomide for Recurrent Glioblastoma
DRKS00022861Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide, aprepitant, minocycline, disulfiram, celecoxib and 5 more in glioblastoma (GBM), sponsored by University Hospital Ulm. Primary endpoint: Safety and tolerability of CUSP9v3 plus metronomic temozolomide. Started Aug 2020; status: completed.
02
Drugs
temozolomideaprepitantminocyclinedisulfiramcelecoxib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on DRKS00022861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00022861.